AU2001268426A1 - Stable gabapentin containing more than 2o ppm of chlorine ion - Google Patents

Stable gabapentin containing more than 2o ppm of chlorine ion

Info

Publication number
AU2001268426A1
AU2001268426A1 AU2001268426A AU6842601A AU2001268426A1 AU 2001268426 A1 AU2001268426 A1 AU 2001268426A1 AU 2001268426 A AU2001268426 A AU 2001268426A AU 6842601 A AU6842601 A AU 6842601A AU 2001268426 A1 AU2001268426 A1 AU 2001268426A1
Authority
AU
Australia
Prior art keywords
ppm
chlorine ion
stable gabapentin
stable
gabapentin containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001268426A
Inventor
Michael Pesachovich
Gideon Pilarski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22788993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001268426(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU2001268426A1 publication Critical patent/AU2001268426A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pharmaceutical compositions containing substantially pure and stable gabapentin are disclosed wherein gabapentin contains an anion of a mineral acid, such as chloride, in amounts greater than 20 ppm.
AU2001268426A 2000-06-16 2001-06-15 Stable gabapentin containing more than 2o ppm of chlorine ion Abandoned AU2001268426A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21196700P 2000-06-16 2000-06-16
US60211967 2000-06-16
PCT/US2001/019100 WO2001097612A1 (en) 2000-06-16 2001-06-15 Stable gabapentin containing more than 2o ppm of chlorine ion

Publications (1)

Publication Number Publication Date
AU2001268426A1 true AU2001268426A1 (en) 2002-01-02

Family

ID=22788993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001268426A Abandoned AU2001268426A1 (en) 2000-06-16 2001-06-15 Stable gabapentin containing more than 2o ppm of chlorine ion

Country Status (12)

Country Link
US (1) US6531509B2 (en)
EP (1) EP1289364B1 (en)
AT (1) ATE255891T1 (en)
AU (1) AU2001268426A1 (en)
CA (1) CA2410867C (en)
DE (2) DE1289364T1 (en)
DK (1) DK1289364T3 (en)
ES (1) ES2193008T3 (en)
IL (1) IL153398A0 (en)
PT (1) PT1289364E (en)
TR (1) TR200302296T4 (en)
WO (1) WO2001097612A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100667721B1 (en) * 2000-06-16 2007-01-15 테바 파마슈티컬 인더스트리즈 리미티드 Stable gabapentin having ph within a controlled range
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
JP2006511624A (en) * 2002-12-20 2006-04-06 ダイノジェン ファーマシューティカルズ， インコーポレイテッド Methods for treating painless bladder disorders using α2δ subunit calcium channel modulators
ES2275229T3 (en) * 2003-03-21 2007-06-01 Dynogen Pharmaceuticals, Inc. METHODS FOR THE TREATMENT OF DISORDERS OF THE URERARY URINARY TRACT USING ANTIMUSCARINES AND MODULATORS OF THE ALFA-2-DELTA SUBUNITY OF THE CALCIUM CHANNEL.
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
US20050163850A1 (en) * 2003-10-31 2005-07-28 Wong Patrick S. Administration of levodopa and carbidopa
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
NL2000281C2 (en) 2005-11-02 2007-08-07 Pfizer Prod Inc Solid pharmaceutical compositions containing pregabalin.
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CN101462975B (en) * 2008-08-19 2012-07-25 宁波九胜创新医药科技有限公司 Preparation of high-purity gabapentin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (en) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-aminomethyl-1-cycloalkaneacetic acids and their esters, processes for their preparation and medicaments containing these compounds
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2611690A1 (en) 1976-03-19 1977-09-22 Goedecke Ag CYCLIC SULFONYLOXYIMIDE
US4960931A (en) 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
US4894476A (en) 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US5319135A (en) 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928182A1 (en) 1989-08-25 1991-02-28 Goedecke Ag METHOD FOR PRODUCING GABAPENTIN
FI107914B (en) 1989-08-25 2001-10-31 Warner Lambert Co An improved process for the preparation of cyclic amino acid compounds and an intermediate used in the process
DE3928184A1 (en) 1989-08-25 1991-02-28 Goedecke Ag METHOD FOR PRODUCING CYCLIC AMINO ACID DERIVATIVES AND INTERMEDIATE PRODUCTS
DE3928183A1 (en) 1989-08-25 1991-02-28 Goedecke Ag LACTAM-FREE CYCLIC AMINO ACIDS
US5132451A (en) 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
BR9910508B1 (en) * 1998-05-15 2012-01-24 stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives.
AU769038B2 (en) * 1998-05-15 2004-01-15 Warner-Lambert Company Llc Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
FR2781793B1 (en) 1998-08-03 2001-07-20 Prographarm Lab PROCESS FOR PRODUCING COATED GABAPENTINE GRANULES
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same

Also Published As

Publication number Publication date
CA2410867A1 (en) 2001-12-27
US6531509B2 (en) 2003-03-11
ES2193008T1 (en) 2003-11-01
DE1289364T1 (en) 2003-09-18
IL153398A0 (en) 2003-07-06
TR200302296T4 (en) 2004-02-23
US20020061931A1 (en) 2002-05-23
EP1289364A4 (en) 2003-08-06
EP1289364B1 (en) 2003-12-10
ES2193008T3 (en) 2004-07-01
WO2001097612A1 (en) 2001-12-27
DE60101476T2 (en) 2004-05-27
CA2410867C (en) 2003-12-09
ATE255891T1 (en) 2003-12-15
PT1289364E (en) 2004-04-30
DE60101476D1 (en) 2004-01-22
DK1289364T3 (en) 2004-04-13
EP1289364A1 (en) 2003-03-12

Similar Documents

Publication Publication Date Title
AU2001268426A1 (en) Stable gabapentin containing more than 2o ppm of chlorine ion
AU7729998A (en) Active principles and gas containing microparticles
YU31399A (en) Nitric oxide synthase inhibitors
HK1045705A1 (en) Silicone gel containing salicylic acid
AU5487996A (en) Dentifrice compositions
AU5488096A (en) Dentifrice compositions
EP0831761A4 (en) Silica abrasive compositions
IL161187A0 (en) Liposome compositions containing metal ions and therapeutic agents
AU5677099A (en) New solid dose form of nanoparticulate naproxen
MXPA04004109A (en) Anhydrous cosmetic compositions containing quaternary ammonium compounds.
AU3722295A (en) Dentifrice compositions
DE69905170D1 (en) Thiazolopyrimidinderivate
EP1499590B8 (en) Piperidine derivatives as potassium channel blockers
AU2002331332A1 (en) Sulfonium salts as phtoinitiators for radiation curable systems
MXPA02006826A (en) Cell division inhibitors and process for producing the same.
CA2469431A1 (en) Stable oral compositions comprising casein phosphopeptide complexes and fluoride
TW200514772A (en) Novel tetrahydropyridine derivatives
HK1023719A1 (en) Stable compositions containing a retinoid and an enzyme based antioxidant system
AU2003293555A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
AU6715500A (en) Water-dispersible agrochemical compositions
AU2003294785A1 (en) Hair treatment compositions
AU2249297A (en) Low ph germicidal iodine compositions having enhanced stability
HRP20030002A2 (en) STABLE GABAPENTIN HAVING pH WITHIN A CONTROLLED RANGE
NZ319138A (en) Composition containing cytochrome complex III and fenazaquin for combatting parasitic fungi